Suscribirse

Beta-elemene: A phytochemical with promise as a drug candidate for tumor therapy and adjuvant tumor therapy - 29/02/24

Doi : 10.1016/j.biopha.2024.116266 
Yewen Feng a, b, c, 1, Qingwen An a, b, c, 1, Zhengqi Zhao a, b, c, 1, Mengting Wu a, b, c, Chuqi Yang a, b, c, WeiYu Liang a, b, c, Xuefei Xu a, b, c, Tao Jiang a, b, c, , Guangji Zhang a, b, c,
a School of Basic Medical Sciences, Zhejiang Chinese Medical University, Zhejiang 310053, China 
b Key Laboratory of Blood-stasis-toxin Syndrome of Zhejiang Province, Zhejiang 310053, China 
c Traditional Chinese Medicine “Preventing Disease” Wisdom Health Project Research Center of Zhejiang, Zhejiang 310053, China 

Correspondence to: School of Basic Medical Sciences, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou, Zhejiang 310053, China.School of Basic Medical Sciences, Zhejiang Chinese Medical University548 Binwen RoadHangzhouZhejiang310053China

Abstract

Background

β-Elemene (IUPAC name: (1 S,2 S,4 R)−1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl) cyclohexane), is a natural compound found in turmeric root. Studies have demonstrated its diverse biological functions, including its anti-tumor properties, which have been extensively investigated. However, these have not yet been reviewed. The aim of this review was to provide a comprehensive summary of β-elemene research, with respect to disease treatment.

Methods

β-Elemene-related articles were found in PubMed, ScienceDirect, and Google Scholar databases to systematically summarize its structure, pharmacokinetics, metabolism, and pharmacological activity. We also searched the Traditional Chinese Medicine System Pharmacology database for therapeutic targets of β-elemene. We further combined these targets with the relevant literature for KEGG and GO analyses.

Results

Studies on the molecular mechanisms underlying β-elemene activity indicate that it regulates multiple pathways, including STAT3, MAPKs, Cyclin-dependent kinase 1/cyclin B, Notch, PI3K/AKT, reactive oxygen species, METTL3, PTEN, p53, FAK, MMP, TGF-β/Smad signaling. Through these molecular pathways, β-elemene has been implicated in tumor cell proliferation, apoptosis, migration, and invasion and improving the immune microenvironment. Additionally, β-elemene increases chemotherapeutic drug sensitivity and reverses resistance by inhibiting DNA damage repair and regulating pathways including CTR1, pak1, ERK1/2, ABC transporter protein, Prx-1 and ERCC-1. Nonetheless, owing to its lipophilicity and low bioavailability, additional structural modifications could improve the efficacy of this drug.

Conclusion

β-Elemene exhibits low toxicity with good safety, inhibiting various tumor types via diverse mechanisms in vivo and in vitro. When combined with chemotherapeutic drugs, it enhances efficacy, reduces toxicity, and improves tumor killing. Thus, β-elemene has vast potential for research and development.

El texto completo de este artículo está disponible en PDF.

Graphical Abstract




El texto completo de este artículo está disponible en PDF.

Highlights

This is a review of the pharmacology, toxicology, and pharmacokinetics of β-elemene.
Beta-elemene has direct anticancer effects and can also act as an adjuvant for chemotherapeutic drugs.
In-depth safety evaluation and formulation studies are required for β-elemene.
Beta-elemene shows promise as a treatment for various types of cancer and tumors.

El texto completo de este artículo está disponible en PDF.

Abbreviations : ABC, ATM, CNS, DOX, ERs, EMT, GO, Hyd, KEGG, NER, NPC, NLCs, NSCLC, TMZ

Keywords : Tumor, Adjuvant therapy, Biological activity, Pharmacology, β-Elemene


Esquema


© 2024  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 172

Artículo 116266- mars 2024 Regresar al número
Artículo precedente Artículo precedente
  • Natural compounds efficacy in Ophthalmic Diseases: A new twist impacting ferroptosis
  • Mengxia Yuan, Qi He, Wang Xiang, Ying Deng, Shibin Lin, Riping Zhang
| Artículo siguiente Artículo siguiente
  • Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets
  • Annoor Awadasseid, Rui Wang, Shishi Sun, Feng Zhang, Yanling Wu, Wen Zhang

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.